Summary
Details
- Global
Mandatory: Parties must implement ABS obligations through national law.
Functionally mandatory: Users must comply with provider country PIC, MAT and permit requirements where applicable.
Stronger requirements: Genetic resources from countries with detailed ABS legislation and traditional knowledge involvement.
Rules vary by country, resource type, date of access and use.
Deep dive
📩 Stay ahead of climate regulation and reporting shifts
Regulatory updates, reporting standards, and new climate software — distilled into one concise weekly brief for decision-makers.
Thanks for signing up. Please check your inbox to confirm your subscription.
Practical updates. Once per week.
What’s Required
The Nagoya Protocol is a supplementary agreement to the Convention on Biological Diversity. Its objective is the fair and equitable sharing of benefits arising from the utilisation of genetic resources, including through appropriate access, technology transfer and funding.
The core architecture includes:
Access rules for genetic resources.
Prior informed consent from provider countries.
Mutually agreed terms between providers and users.
Benefit-sharing obligations.
Traditional knowledge associated with genetic resources.
Compliance checkpoints.
Internationally Recognized Certificates of Compliance.
ABS Clearing-House.
National focal points and competent authorities.
This creates a biodiversity-derived value governance model, where commercial or research use of genetic resources must respect provider country rules and benefit-sharing terms.
1. Access to Genetic Resources
Users may need authorisation before accessing genetic resources.
This affects:
Biological samples.
Plants.
Microorganisms.
Marine genetic resources where national jurisdiction applies.
Seeds.
Fungi.
Animal genetic material.
Soil organisms.
Natural compounds.
Biochemical extracts.
Access rules depend on provider country law. Companies must check national ABS rules before collecting, importing, researching or commercialising genetic resources.
2. Prior Informed Consent and Mutually Agreed Terms
Two central compliance concepts are:
Prior Informed Consent, or PIC.
Mutually Agreed Terms, or MAT.
PIC means the provider country or authorised community agrees to access. MAT defines benefit-sharing and conditions of use.
Benefits can include:
Monetary payments.
Royalties.
Research collaboration.
Technology transfer.
Capacity building.
Training.
Joint publications.
Local employment.
Conservation funding.
Sharing of research results.
This creates a contractual biodiversity compliance model, where legal access and benefit-sharing depend on documented permission and agreed terms.
3. Traditional Knowledge Associated with Genetic Resources
The Protocol also covers traditional knowledge associated with genetic resources held by indigenous peoples and local communities.
This affects:
Ethnobotanical research.
Traditional medicine.
Natural cosmetics.
Food ingredients.
Agricultural practices.
Bioprospecting.
Cultural knowledge linked to biological resources.
Users may need community consent and benefit-sharing arrangements depending on national law.
This creates a rights-based bioeconomy governance layer, where sustainability includes fairness, community participation and respect for traditional knowledge.
4. ABS Clearing-House and Compliance Certificates
The ABS Clearing-House is the official information platform for the Protocol. It supports exchange of information on national ABS measures, focal points, permits and Internationally Recognised Certificates of Compliance.
Companies should use it to check:
Provider country rules.
Competent national authorities.
National focal points.
Model clauses or procedures.
Issued certificates.
Compliance checkpoints.
This creates a digital compliance infrastructure, where genetic resource access can be traced through official documentation.
5. Supply Chain and Product Implications
The Nagoya Protocol affects sectors that use biodiversity-derived materials.
Relevant sectors include:
Pharmaceuticals.
Cosmetics.
Biotechnology.
Food and beverages.
Agriculture.
Seeds.
Crop breeding.
Natural flavours and fragrances.
Enzymes.
Nutraceuticals.
Academic research.
Synthetic biology.
Companies need to determine:
Was a genetic resource accessed after the Nagoya rules applied?
Which country provided it?
Was PIC required and obtained?
Were MATs signed?
Is traditional knowledge involved?
Are benefits being shared?
Does downstream commercialisation change obligations?
This creates a biodiversity supply chain due diligence model.
6. Digital Sequence Information Challenge
A major current issue is digital sequence information, or DSI.
The Nagoya Protocol was designed around genetic resources, but modern research often uses digitised genetic sequence data stored in databases. This has created debate about whether and how benefits from DSI should be shared.
Recent biodiversity negotiations have focused on mechanisms for DSI benefit-sharing, because the original Nagoya model does not easily cover all digital genetic data use. Reporting around COP16 highlighted tensions over DSI, equity and benefit-sharing for sectors such as pharmaceuticals, cosmetics and biotechnology.
This creates an emerging compliance uncertainty layer, especially for biotech and life sciences companies.
Important Deadlines
Key timelines include:
2010: Nagoya Protocol adopted.
2014: Nagoya Protocol entered into force. The CBD states it entered into force on 12 October 2014.
Ongoing: Countries publish national ABS measures through the ABS Clearing-House.
Ongoing: Users must comply with provider country access and benefit-sharing rules.
Ongoing: Internationally Recognised Certificates of Compliance are issued for access permits.
Current Status
The Nagoya Protocol is active and increasingly relevant to biodiversity-linked industries.
Current focus areas include:
ABS compliance.
Traditional knowledge.
DSI benefit-sharing.
Provider country enforcement.
User country due diligence.
Bioprospecting.
Natural ingredients.
Indigenous and local community rights.
Biodiversity finance.
Recent reporting indicates that India has become a leading issuer of Internationally Recognised Certificates of Compliance, showing growing use of formal ABS documentation.
Penalties for Non-Compliance
Potential consequences include:
Loss of access permits.
Research delays.
Market access barriers.
Contract claims.
Benefit-sharing disputes.
Product commercialisation risk.
Reputational damage.
Legal penalties under national ABS laws.
Loss of partnerships with provider countries or communities.
Examples of Known Violations
Typical violations and failure modes include:
Accessing genetic resources without prior informed consent where required.
Using genetic resources without mutually agreed terms.
Commercialising research results beyond the scope of the original access permit.
Failing to share monetary or non-monetary benefits with the provider country or authorised community.
Using traditional knowledge associated with genetic resources without required consent.
Not keeping documentation such as permits, MAT agreements or internationally recognised certificates of compliance.
Transferring genetic resources to downstream partners without passing on ABS obligations.
Misidentifying the country of origin or source of genetic material.
Treating digital sequence information as outside compliance without checking current national or international requirements.
Failing to monitor provider country ABS laws before collection, research or commercialization.
Resources
Cut through the green tape
We don't push agendas. At Net Zero Compare, we cut through the hype and fear to deliver the straightforward facts you need for making informed decisions on green products and services. Whether motivated by compliance, customer demands, or a real passion for the environment, you’re welcome here. We provide reliable information. Why you seek it is not our concern.